Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




C - Reactive Protein Measurement Aids Assessment of Bowel Disease

By LabMedica International staff writers
Posted on 03 Aug 2010
The level of C-reactive protein in the blood is used to assess disease activity in diverse inflammatory disorders including inflammatory bowel disease (IBD).

High-sensitivity CRP (hs-CRP) measures CRP levels that were previously thought to be under the detection limit. In pediatric IBD, this kind of highly sensitive marker is needed for the detection of the presence of inflammation.

Inflammatory bowel disease is a chronic, relapsing, and remitting disease of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. CRP is an acute phase protein produced by liver that is used in the diagnosis of inflammatory disorders. Serum hs-CRP can be analyzed using enzyme linked immunoassays (ELISA) kits. A team from Finland investigated the association between hs-CRP and clinical and histological activity in pediatric IBD patients, and evaluated the effect of glucocorticoid treatment on the hs-CRP levels.

The serum samples from 39 Finnish children with IBD were analyzed using a human C-reactive protein Instant ELISA kit (Bender MedSystems GmbH, Vienna, Austria; www.bendermedsystems.com). A further 22 children with IBD and followed for acute response to glucocorticoids, and 33 pediatric non-IBD patient were also tested. The hs-CRP Instant ELISA kit has an intra-assay coefficient of variation (C.V.) of 6.9%, and an interassay C.V. of 13.1% and detection limit of 3 × 10-6 mg/L.

The study, carried out at the University of Helsinki (Helsinki, Finland), showed that standard CRP test is negative in a considerable number of pediatric patients with active IBD and the routine measurement of CRP is thus not informative enough. The hs-CRP test detects low levels of CRP, but disappointingly, it does not help to distinguish children with active intestinal inflammation from those with quiescent disease or those responding to glucocorticoid treatment from nonresponders. Interestingly, the levels of hs-CRP correlated with the presence of ileal inflammation.

This study reinforces the concept that a significant number of pediatric patients with active IBD may present with CRP levels that are under the detection limit. Here, standard CRP was under the detection limit of 5 mg/L in 60% of the young patients with active colitis. All patients with undetectable standard CRP had measurable hs-CRP levels, but there was no cut-off value for low CRP values with which to differentiate active and dormant disease. The results of the clinical investigation were published on June 21, 2010, in the World Journal of Gastroenterology.

Related Links:

Bender MedSystems GmbH
University of Helsinki





Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.